Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells

Wang,Cheng-Kun; Zhang,Yang; Zhang,Zhi-Jie; Qiu,Qin-Wei; Cao,Jian-Guo; He,Zhi-Min

doi:10.3892/or.2014.3607

Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells

Authors:
- Cheng-Kun Wang
- Yang Zhang
- Zhi-Jie Zhang
- Qin-Wei Qiu
- Jian-Guo Cao
- Zhi-Min He
View Affiliations

Affiliations: Cancer Research Institute, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guandong 510182, P.R. China, Cancer Research Institute, University of South China, Hunan, Hengyang 421001, P.R. China, Medical College, Hunan Normal University, Hunan, Changsha 410006, P.R. China
Published online on: November 13, 2014 https://doi.org/10.3892/or.2014.3607
Pages: 372-382

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor drug resistance is a major obstacle to cancer chemotherapy. We previously constructed a fusion protein based on two tumstatin-derived sequences named recombinant VBMDM (rVBMDMP). We preliminarily confirmed its inhibition of HUVEC and colon cancer cell growth. The present study further systematically observed the inhibitory effect of rVBMDMP on lung cancer cell growth and analyzed a possible mechanism to provide a theoretical basis for the development of new antitumor protein drugs. The effect of rVBMDMP on human lung adenocarcinoma (A549) and cisplatin-resistant human lung adenocarcinoma (A549/DDP) cell proliferation was evaluated by MTS assay. Hoechst 33342 staining performed together with fluorescence microscopy and immunoblot analysis were used to examine the effects of rVBMDMP on the apoptosis of A549/DDP cells. A protein phosphorylation chip was used to identify changes in rVBMDMP-induced signaling protein phosphorylation. Changes in the phosphatidylinositol 3 kinase (PI3K)/Akt signal transduction pathway and expression of multidrug resistance protein (MRP-2)-related molecules following rVBMDMP treatment in A549/DDP cells were evaluated by western blot analysis. A lung cancer xenograft model was used to evaluate the reversal effect of rVBMDMP on drug-resistance of A549/DDP cell tumors to cisplatin in vivo. The results demonstrated that rVBMDMP increased the phosphorylation of 79 signaling proteins, including focal adhesion kinase (FAK), caspase-6, Fas, FasL and FAF1 and downregulated 30 signaling proteins, including integrin αV, integrin β3, PI3K/Akt, NF-κB and MRP-2 compared with the controls. rVBMDMP also increased the sensitivity of A549 and A549/DDP cells to cisplatin and directly induced apoptosis, which may be related to MRP-2 and Bcl-2 downregulation. The effects of growth inhibition and apoptosis induction of rVBMDMP on A549/DDP cells may be related to the inhibition of integrin αVβ3 and PI3K/Akt protein phosphorylation. Finally, we observed an increase in cancer cell sensitivity to cisplatin by rVBMDMP using the A549/DDP cell xenograft model in nude mice. Our study suggests that rVBMDMP may be an effective potential chemotherapy sensitizer and may be a viable drug candidate in anticancer therapies.

View Figures

View References

1	Peng SP, Fang WY, Dai WJ, Zou XQ, Liu HY and Cao JG: Cloning expression and space conformation analysis of vascular basement membrane-derived multifunctional peptide. Chinese J Cancer Biother. 10:185–189. 2003.
2	Peng SP, Fang WY, Jiang RC, Zhou JG and Cao JG: Prokaryotic expression of vascular basement membrane-derived multi-functional peptide and its anti-tumor activity assay. Zhongguo Yaolixue Tongbao. 19:678–682. 2003.
3	Cao JG, Peng SP, Sun L, Li H, Wang L and Deng HW: Vascular basement membrane-derived multifunctional peptide, a novel inhibitor of angiogenesis and tumor growth. Acta Biochim Biophys Sin (Shanghai). 38:514–521. 2006. View Article : Google Scholar
4	Wang C, Cao J, Qu J, Li Y, Peng B, Gu Y and He Z: Recombinant vascular basement membrane derived multifunctional peptide blocks endothelial cell angiogenesis and neovascularization. J Cell Biochem. 111:453–460. 2010. View Article : Google Scholar : PubMed/NCBI
5	Desgrosellier JS and Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar
6	Long QZ, Zhou M, Liu XG, Du YF, Fan JH, Li X and He DL: Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells. Anticancer Drugs. 24:810–817. 2013. View Article : Google Scholar : PubMed/NCBI
7	Wang CK, Cao JG, Peng B, Gu YX, Zheng GP and He ZM: Inhibition of growth and motility of human A549 lung carcinoma cells by a recombined vascular basement membrane derived peptide. Cancer Lett. 292:261–268. 2010. View Article : Google Scholar : PubMed/NCBI
8	Scheer N, Balimane P, Hayward MD, Buechel S, Kauselmann G and Wolf CR: Generation and characterization of a novel multidrug resistance protein 2 humanized mouse line. Drug Metab Dispos. 40:2212–2218. 2012. View Article : Google Scholar : PubMed/NCBI
9	Tiwari AK, Sodani K, Dai CL, et al: Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2- and ABCC10-multidrug resistance xenograft models. Cancer Lett. 328:307–317. 2013. View Article : Google Scholar
10	Laitinen EM, Vaaralahti K, Tommiska J, Eklund E, Tervaniemi M, Valanne L and Raivio T: Incidence, phenotypic features and molecular genetics of Kallmann syndrome in Finland. Orphanet J Rare Dis. 6:412011. View Article : Google Scholar : PubMed/NCBI
11	Shahan TA, Ziaie Z, Pasco S, Fawzi A, Bellon G, Monboisse JC and Kefalides NA: Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer Res. 59:4584–4590. 1999.PubMed/NCBI
12	Huang XW, Wang JY, Li F, Song ZJ, Xie C and Lu WY: Biochemical characterization of the binding of cyclic RGDyK to hepatic stellate cells. Biochem Pharmacol. 80:136–143. 2010. View Article : Google Scholar : PubMed/NCBI
13	Huang CY, Fong YC, Lee CY, Chen MY, Tsai HC, Hsu HC and Tang CH: CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol. 77:794–803. 2009. View Article : Google Scholar
14	Ummanni R, Teller S, Junker H, et al: Altered expression of tumor protein D52 regulates apoptosis and migration of prostate cancer cells. FEBS J. 275:5703–5713. 2008. View Article : Google Scholar : PubMed/NCBI
15	Jiang P, Enomoto A and Takahashi M: Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett. 284:122–130. 2009. View Article : Google Scholar : PubMed/NCBI
16	Winograd-Katz SE, Fassler R, Geiger B and Legate KR: The integrin adhesome: from genes and proteins to human disease. Nat Rev Mol Cell Biol. 15:273–288. 2014. View Article : Google Scholar : PubMed/NCBI
17	Bouvard D, Pouwels J, De Franceschi N and Ivaska J: Integrin inactivators: balancing cellular functions in vitro and in vivo. Nat Rev Mol Cell Biol. 14:430–442. 2013. View Article : Google Scholar : PubMed/NCBI
18	Hu P and Luo BH: Integrin bi-directional signaling across the plasma membrane. J Cell Physiol. 228:306–312. 2013. View Article : Google Scholar
19	Yin B: Focal adhesion kinase as a target in the treatment of hematological malignancies. Leuk Res. 35:1416–1418. 2011. View Article : Google Scholar : PubMed/NCBI
20	Riaz A, Ilan N, Vlodavsky I, Li JP and Johansson S: Characterization of heparanase-induced phosphatidylinositol 3-kinase-AKT activation and its integrin dependence. J Biol Chem. 288:12366–12375. 2013. View Article : Google Scholar : PubMed/NCBI
21	Guenther MK, Graab U and Fulda S: Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Lett. 337:200–209. 2013. View Article : Google Scholar : PubMed/NCBI
22	Choi BH, Kim CG, Lim Y, Shin SY and Lee YH: Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 259:111–118. 2008. View Article : Google Scholar
23	Goler-Baron V, Sladkevich I and Assaraf YG: Inhibition of the PI3K-Akt signaling pathway disrupts ABCG2-rich extracellular vesicles and overcomes multidrug resistance in breast cancer cells. Biochem Pharmacol. 83:1340–1348. 2012. View Article : Google Scholar : PubMed/NCBI
24	Konopleva MY, Walter RB, Faderl SH, et al: Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 20:2226–2235. 2014. View Article : Google Scholar : PubMed/NCBI
25	Neri LM, Cani A, Martelli AM, et al: Targeting the PI3K/ Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 4:739–748. 2014. View Article : Google Scholar
26	Chen KC, Yang TY, Wu CC, et al: Pemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway. PLoS One. 9:e978882014. View Article : Google Scholar : PubMed/NCBI
27	Wang F, Li T, Zhang B, et al: MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun. 434:688–694. 2013. View Article : Google Scholar : PubMed/NCBI
28	Ning J and Clemmons DR: AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol Endocrinol. 24:1218–1229. 2010. View Article : Google Scholar : PubMed/NCBI
29	Liu L, Dai Y, Chen J, et al: Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling. Hepatology. 59:531–543. 2014. View Article : Google Scholar
30	Bak Y, Kim H, Kang JW, et al: A synthetic naringenin derivative, 5-hydroxy-7,4′-diacetyloxyflavanone-N-phenyl hydrazone (N101–43), induces apoptosis through up-regulation of Fas/FasL expression and inhibition of PI3K/Akt signaling pathways in non-small-cell lung cancer cells. J Agric Food Chem. 59:10286–10297. 2011. View Article : Google Scholar : PubMed/NCBI
31	Krzyzowska M, Shestakov A, Eriksson K and Chiodi F: Role of Fas/FasL in regulation of inflammation in vaginal tissue during HSV-2 infection. Cell Death Dis. 2:e1322011. View Article : Google Scholar : PubMed/NCBI
32	Shenoy AR, Kirschnek S and Hacker G: IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells. Eur J Immunol. 2500–2507. 2014. View Article : Google Scholar : PubMed/NCBI
33	Bogdal MN, Hat B, Kochanczyk M and Lipniacki T: Levels of pro-apoptotic regulator Bad and anti-apoptotic regulator Bcl-xL determine the type of the apoptotic logic gate. BMC Syst Biol. 7:672013. View Article : Google Scholar : PubMed/NCBI
34	Gravina GL, Marampon F, Giusti I, et al: Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Int J Oncol. 40:711–720. 2012.
35	Wang TE, Wang YK, Jin J, Xu BL and Chen XG: A novel derivative of quinazoline, WYK431 induces G2/M phase arrest and apoptosis in human gastric cancer BGC823 cells through the PI3K/Akt pathway. Int J Oncol. 45:771–781. 2014.PubMed/NCBI
36	Liu Z, Sun C, Zhang Y, Ji Z and Yang G: Phosphatidylinositol 3-kinase-C2β inhibits cisplatin-mediated apoptosis via the Akt pathway in oesophageal squamous cell carcinoma. J Int Med Res. 39:1319–1332. 2011. View Article : Google Scholar
37	Le Vee M, Jouan E, Stieger B, Lecureur V and Fardel O: Regulation of drug transporter expression by oncostatin M in human hepatocytes. Biochem Pharmacol. 82:304–311. 2011. View Article : Google Scholar : PubMed/NCBI
38	Ishikawa T, Wright CD and Ishizuka H: GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem. 269:29085–29093. 1994.PubMed/NCBI
39	Kibria G, Hatakeyama H and Harashima H: Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 37:4–15. 2014. View Article : Google Scholar